GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at ... FDA and has called for ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GlaxoSmithKline (GSK) Company Description: In the pharmaceutical industry ... as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Pharmaceutical and agricultural companies are among the industry groups pushing against a proposed levy on their returns from ...